SINGAPORE – 04 January 2019 – Enleofen Bio Pte Ltd (“Enleofen”), a biotechnology company developing first-in-class therapeutics for the treatment of fibro-inflammatory human diseases, today announced ENx108A, a human antibody, as its first clinical development lead. The antibody is a powerful inhibitor of Interleukin 11 (“IL-11”), a protein that is the master driver of fibrosis and determinant of tissue inflammation across body organs such as the liver, lung and kidney.
08 February 18 – Norbert Hubner, Todd Juan, Tracy Putoczki, Shelia Violette and Tina Wong have joined Enleofen’s Scientific Advisory Board. Please find further details on the page “Our Team”.
Cambridge, UK and Singapore, 14 November 2017 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, works with Enleofen Bio Pte Ltd (‘Enleofen Bio), to develop first-in-class antibody therapeutics for the treatment of fibrotic human diseases.
SINGAPORE – 14 November 2017 – Enleofen Bio Pte Ltd (“Enleofen”) today announced a breakthrough in the quest for novel and effective fibrosis therapies, based on ground-breaking research published in Nature, the leading scientific journal…
SINGAPORE – 1 November 2017 – Enleofen Co-Founder Sebastian Schäfer will be presenting compelling data during the Anti-Fibrotic Drug Development Summit (AFDD) in Boston, USA, from 13-14 November 2017…
28 August 2017 – A breakthrough discovery in the field of cardiovascular fibrosis research made at Duke-NUS Medical School (Duke-NUS) and National Heart Centre Singapore (NHCS) has been licensed to a newly launched company Enleofen Bio Pte Ltd, a Singapore-funded biotechnology start-up.
11 August 17 – The ESC Congress 2017 will take place from 26 – 30 August 2017 in Barcelona, Spain. It is the world’s largest cardiovascular congress with over 500 experts sessions and more than 4,500 abstracts contributing to the advancement of cardiovascular medicine worldwide.
04 April 17 – Enleofen Bio Pte. Ltd. was founded as a spin-out from National Heart Centre Singapore (NHCS), SingHealth and Duke-NUS Medical School with Series A funding. Enleofen develops first-in-class antibody therapeutics for the treatment of fibrotic human diseases.